Kelly A. Johnson has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Kathleen Jacobson

    Office of Sexually Transmitted Infections (STIs) and Hepatitis C (HCV), Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health , Richmond, California

    5 shared publications
  • Eric C. Tang

    Sexually Transmitted Diseases Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health , Richmond, California , USA

    3 shared publications
  • Hideaki Okochi

    Department of Medicine, University of California San Francisco , San Francisco, California , USA

    3 shared publications
  • Stephanie E. Cohen

    Division of Infectious Diseases, University of California San Francisco, San Francisco, USA

    3 shared publications
  • Eric C. M.D. Tang

    Sexually Transmitted Diseases (STD) Control Branch, Division of Communicable Disease Control (DCDC), Center for Infectious Diseases (CID), California Department of Public Health (CDPH), Richmond

    2 shared publications
  • Monica Gandhi

    Department of Medicine, University of California San Francisco , San Francisco, California , USA

    2 shared publications

Latest Publications

  • Open Access

    Trends and Themes in Mycoplasma genitalium Consultations Received Through the Sexually Transmitted Diseases Clinical Consultation Network 2015–2024

    by Jacob McLean, Jacqueline Sherbuk, Wyatt Hanft, Kelly A Johnson, Barbara Wilgus, Destiny Kelley, Nicholas Van Wagoner, William M Geisler

    Background: Mycoplasma genitalium is an emerging sexually transmitted pathogen. M. genitalium is often asymptomatic but can cause urethritis, is associated with cervicitis and pelvic inflammatory disease, and possibly infertility and premature labor. Although multiplex sexually transmitted infection (STI) testing platforms that include M. genitalium are available, screening for asymptomatic infection is not recommended as its potential clinical impact is unknown. Leveraging the STD Clinical Consultation Network (STDCCN)—an STI consultation service for healthcare and public health professionals in the USA—our study aimed to identify training needs by analyzing temporal and thematic trends in M. genitalium consultations. Methods: We reviewed STDCCN consults referencing “Mycoplasma,” “genitalium,” “m gen” and “mgen” between 2015 and 2024. Consult data were extracted, reviewed by 2 groups of 2 authors (with another reviewer adjudicating disagreements), and categorized by theme(s) and patient characteristics. Results: 336 M. genitalium consults were identified, of which 75% occurred after 1 January 2023. Common themes were management in pregnancy (42%) and treatment failure (35%). Pregnant patients were less likely than nonpregnant patients to have symptoms reported. Consults pertaining to M. genitalium versus other topics were more likely to come from providers (physicians, nurse practitioners, nurse midwives, and physician assistants) than individuals in other roles, and more likely to come from individuals in private practices or women's health clinics than other practice settings. Conclusions: STDCCN observed a substantial increase in M. genitalium consultations starting in 2023. This rise was likely driven by M. genitalium treatment failures and detection of M. genitalium in asymptomatic pregnant people. This study highlights the need for provider education about appropriate use of M. genitalium diagnostics, indications for M. genitalium screening/testing, and management of M. genitalium treatment failures.

  • Open Access

    Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022

    by Kelly A Johnson, Roshani Fernando, Rosalyn Plotzker, Nicole O Burghardt, Robert E Snyder, Wyatt Hanft, Kurtis Mohr, Lizzete Alvarado, Gwenyth Crise, Eric C Tang, et al.

    Odds of disseminated versus uncomplicated gonorrhea increased among people not prioritized for routine uncomplicated gonorrhea screening, including men who only had sex with female partners (odds ratio [OR] 10.8; 95% confidence interval [CI], 4.8–24.1), people using substances (OR 10.0; 95% CI, 5.4–18.6), and older people (OR 1.09 per year; 95% CI, 1.07–1.11).


  • Open Access

    Implementing a 24/7 Congenital Syphilis Hotline for California Clinicians: Results From a 13-Week Pilot Project

    by Helen Burnside, Destiny Bs Kelley, Ina U. Park, Hilary Reno, Karen Wendel, Mariska DrPH Osborne-Wells, Brea Ford, Alexandra Coor, Lindley A. Barbee, Laura A.S. Quilter, et al.

    The National Network of STD Prevention Training Centers launched a 24 hours/7 days a week hotline pilot for consultations on syphilis during pregnancy and congenital syphilis. Most of the 28 urgent requests were from physicians (61%) in hospitals (54%), involving patients in their third trimester or recently born infants (82%).


  • Open Access

    Comparing 7-Day Versus 6–8-Day Penicillin Treatment Intervals Among Pregnant People With Syphilis of Late or Unknown Duration: No Difference Found in Incidence of Congenital Syphilis

    by Kelly A Johnson, Nicole O Burghardt, Robert E Snyder, Rosalyn E Plotzker, Brandon M Imp, Ryan Murphy, Kathleen Jacobson, Eric C Tang

    Background: Guidelines recommend that pregnant patients with syphilis of late/unknown duration be treated with benzathine penicillin G, dosed as 3 weekly intramuscular injections (BPGx3) given ideally at strict 7-day intervals. Given limited pharmacokinetic data, it is unknown whether more flexible BPG treatment intervals might be effective in preventing congenital syphilis (CS). Methods: We used California surveillance data to identify birthing parent/infant dyads wherein the pregnant parent had syphilis of late/unknown duration between January 1, 2016 – June 30, 2019. We divided the dyads into 3 groups based on prenatal treatment: (1) BPGx3 at strict 7-day intervals, (2) BPGx3 at 6-8 day intervals, and (3) no/inadequate treatment. We then compared CS incidence among infants in each group. Results: We analyzed 1,092 parent/infant dyads: 607 (55.6%) in the 7-day treatment group, 70 (6.4%) in the 6–8 day treatment group, and 415 (38.0%) in the no/inadequate treatment group. The incidence proportion of infants meeting CS criteria in each group was, respectively, 5.6%, 5.7%, and 36.9%. Compared with BPGx3 at 7-day intervals, the odds of CS were 1.0 [95% CI 0.4–3.0] in the 6–8 day group and 9.8 [95% CI 6.6–14.7] in the no/inadequate treatment group. Conclusions: Prenatal BPGx3 at 6–8 days was no more likely to lead to CS in infants than 7-days. These findings hint that 6-8-day intervals might be adequate to prevent CS among pregnant people with syphilis of late/unknown duration. Consequently, it is possible that CS evaluation beyond an RPR at delivery may be unnecessary in asymptomatic infants whose parents received BPGx3 at 6–8 days.


  • Disseminated Gonococcal Infections—Lessons Learned From an Ongoing California Public Health Investigation

    by Kelly A. M.D. Johnson, Eric C. M.D. Tang, Lizzete M.P.H Alvarado, Cindy L. Hernandez, Roshani Fernando, Nicole O. Burghardt, Robert E. Ph.D. Snyder, Krysta L. Salas, Roberto Franco, Melissa M.A. Marston, et al.

    An abstract is unavailable. This article is available as a PDF only.


  • Testing for Mycoplasma genitalium and Using Doxycycline as First-Line Therapy at Initial Presentations for Non-Gonococcal Urethritis (NGU) Correlate With Reductions in Persistent NGU

    by Kelly A Johnson, Madeline Sankaran, Robert P Kohn, Oliver Bacon, Stephanie E Cohen

    We found that the odds of return clinic visits for persistent non-gonococcal urethritis (pNGU) were significantly lower (OR 0.4, 95% CI 0.3-0.6, p < 0.0001) after implementing: (1) testing for Mycoplasma genitalium during initial evaluations for non-gonococcal urethritis (NGU) and (2) switching from azithromycin to doxycycline as first-line NGU treatment.


  • Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-Based Antiretroviral Therapy

    by Kelly A Johnson, Hideaki Okochi, Mireya Arreguin, Joseph Watabe, David V Glidden, Anindita Chattopadhyay, Elizabeth Imbert, Matthew D Hickey, Monica Gandhi, Matthew Spinelli

    We found that urine tenofovir (TFV) levels >1500 ng/mL strongly predict virologic suppression among people with human immunodeficiency virus taking tenofovir alafenamide (odds ratio, 5.66; 95% confidence interval, 1.59–20.14; P = .007). This suggests an existing point-of-care assay developed for tenofovir disoproxil fumarate will support adherence monitoring for patients on all TFV-based antiretrovirals.


  • Open Access

    Texting Lost-to-follow-up PrEP Patients from a San Francisco Sexual Health Clinic

    by Kelly A. Johnson, Montica Levy, Hannah Brosnan, Robert P. Kohn, Stephanie E. Cohen

    It is critical to understand what happens when PrEP patients are lost-to-follow-up (LTFU) and, where appropriate, attempt to re-engage them in care with the goal of preventing future human immunodeficiency virus (HIV) acquisition. We evaluated the benefits and limitations of using text-based outreach to re-engage with LTFU PrEP patients and offer re-initiation of PrEP care. Using text-messaging, we surveyed San Francisco City Clinic patients who started PrEP from January 2015 to October 2019 and were LTFU by October 1, 2020. Our goals were to better understand (1) whether our patients remained on PrEP through another provider or source, (2) why patients choose to discontinue PrEP, and (3) whether text-based outreach could successfully re-engage such patients in care. Multiple-choice survey questions were analyzed quantitatively to determine the proportion of respondents selecting each option; free-text responses were analyzed qualitatively using an inductive approach to identify any additional recurring themes. Of 846 eligible survey recipients, 130 responded (overall response rate 15.4%). Forty-two respondents (32.3%) were still on PrEP through another provider while 88 (67.7%) were not. Common reasons for stopping PrEP included: COVID-19–related changes in sex life (32.3% of responses), concerns regarding side effects (17.7%), and the need to take a daily pill (8.3%). Free text responses revealed additional concerns regarding risk compensation. While 32 participants agreed to be contacted by City clinic staff for PrEP counseling, only 6 were reached by phone and none of the six subsequently restarted PrEP. We learned that text messaging is a possible approach to survey certain PrEP program participants to determine who is truly LTFU and off PrEP, and to better understand reasons for PrEP discontinuation. While such information could prove valuable as programs seek to address barriers to PrEP retention, efforts to improve acceptability and increase response rates would be necessary. We were less successful in re-engaging LTFU patients in PrEP care, suggesting that text-messaging may not be the optimal strategy for this purpose.


  • Open Access

    Geospatial Social Determinants of Health Correlate with Disparities in Syphilis and Congenital Syphilis Cases in California

    by Kelly A. Johnson, Robert E. Snyder, Eric C. Tang, Natalie S. de Guzman, Rosalyn E. Plotzker, Ryan Murphy, Kathleen Jacobson

    Syphilis and congenital syphilis (CS) are increasing in California (CA). From 2015 through 2019, for example, CA cases of early syphilis among reproductive-age females (15–44) and CS each increased by >200%. Certain populations—including people experiencing homelessness, using drugs, and/or belonging to certain racial/ethnic groups—have been disproportionately impacted. We hypothesized that geospatial social determinants of health (SDH) contribute to such health inequities. To demonstrate this, we geospatially described syphilis in CA using the Healthy Places Index (HPI). The HPI is a composite index that assigns a score to each CA census tract based on eight socioeconomic characteristics associated with health (education, housing, transportation, neighborhood conditions, clean environment, and healthcare access as well as economic and social resources). We divided CA census tracts into four quartiles based on HPI scores (with the lowest quartile having the least healthy socioeconomic and environmental conditions), then used 2013–2020 CA sexually transmitted diseases surveillance data to compare overall syphilis (among adults and adolescents) and CS case counts, incidence rates (per 100,000 population or live births), and incidence rate ratios (IRRs) among these quartiles. From 2013 to 2020, across all stages of syphilis and CS, disease burden was greatest in the lowest HPI quartile and smallest in the highest quartile (8308 cases (representing 33.2% of all incidents) versus 3768 (15.1%) for primary and secondary (P&S) syphilis; 5724 (31.6%) versus 2936 (16.2%) for early non-primary non-secondary (NPNS) syphilis; 11,736 (41.9%) versus 3026 (10.8%) for late/unknown duration syphilis; and 849 (61.9%) versus 57 (4.2%) for CS; all with p < 0.001). Using the highest HPI quartile as a reference, the IRRs in the lowest quartile were 17 for CS, 4.5 for late/unknown duration syphilis, 2.6 for P&S syphilis, and 2.3 for early NPNS syphilis. We thus observed a direct relationship between less healthy conditions (per HPI) and syphilis/CS in California, supporting our hypothesis that SDH correlate with disparities in syphilis, especially CS. HPI could inform allocation of resources to: (1) support communities most in need of assistance in preventing syphilis/CS cases and (2) reduce health disparities.